Article: Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia.

HAMBURG, Germany and OXFORD, England, August 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at 11.00 am CET / 10.00 am GMT / 5.00 am EST / 7.00 pm AEST

The Evotec speakers at the worldsleep07 congress and in the webcast and conference call will be:

 
  - Dr John Kemp, Chief Research and Development Officer 
  - Dr Tim Tasker, Executive Vice President Clinical Development 
 

Evotec will host a poster presentation on the study results at the worldsleep07 ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!